These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 93529)

  • 41. Immunodiagnosis of prostate cancer: an evaluation of cell-mediated immunity.
    Bhatti RA; Guinan PD; Nagubadi SR; Khin W
    Prostate; 1982; 3(4):415-9. PubMed ID: 7122334
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A contribution to immunological tumour diagnostics in urology.
    Günther M; Friedrich A; Erdmann T; Jenssen HL; Werner H; Seyfarth M; Köhler H
    Int Urol Nephrol; 1978; 10(2):111-5. PubMed ID: 81191
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer. I. Thymic-dependent lymphocytic blastogenesis.
    Ablin RJ; Bruns GR; Guinan PD; Bush IM
    Urol Int; 1976; 31(5):374-82. PubMed ID: 64009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Suppression of tumor-associated immunity by human seminal plasma and its possible role in the natural history of prostatic cancer.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    Eur Urol; 1980; 6(4):225-8. PubMed ID: 7389776
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. II. Tissue- and disease-specificity of antitumour cell-mediated immunity.
    Bhatti RA; Ablin RJ; Guinan PD
    Eur J Cancer (1965); 1979 Jan; 15(1):133-6. PubMed ID: 421713
    [No Abstract]   [Full Text] [Related]  

  • 46. Comparison of serum blocking factors on leucocyte adherence inhibition and PHA lymphocyte blastogenesis in breast cancer patients.
    Fujisawa T; Yonemoto RH; Waldman SR
    Jpn J Surg; 1981; 11(6):406-12. PubMed ID: 6799680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunosuppression of cell- and serum-medicated tumour-associated immunity in prostatic cancer by human seminal plasma.
    Ablin RJ; Bhatti RA; Bush IM; Guinan PD
    Eur J Cancer (1965); 1980 Jun; 16(6):775-80. PubMed ID: 7408927
    [No Abstract]   [Full Text] [Related]  

  • 48. Effect of estrogen on the mixed lymphocyte reaction in normal individuals and prostatic cancer patients.
    Herr HW
    Prostate; 1982; 3(1):17-21. PubMed ID: 6210901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T-antigen does not induce cell mediated immunity in patients with breast cancer.
    Howard DR
    Cancer; 1983 Jun; 51(11):2053-6. PubMed ID: 6839295
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer.
    Pizza G; De Vinci C; Cuzzocrea D; Menniti D; Aiello E; Maver P; Corrado G; Romagnoli P; Dragoni E; LoConte G; Riolo U; Palareti A; Zucchelli P; Fornarola V; Viza D
    Biotherapy; 1996; 9(1-3):123-32. PubMed ID: 8993770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunologic responsiveness of patients with cancer: relationship to tumor type, stage and prognosis.
    Humphrey LJ; Humphrey MA; Singla O; Volenec FJ
    Ann Surg; 1981 May; 193(5):574-8. PubMed ID: 7235762
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of human seminal plasma on tumour-associated immunity in prostatic cancer. A preliminary report.
    Ablin RJ; Bhatti RA; Guinan PD; Bush IM
    Experientia; 1979 Nov; 35(11):1510-11. PubMed ID: 510506
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Leukocyte adherence inhibition and immunoreactivity in prostatic cancer. I. Identification of anti-tumour cell-mediated immunity and "blocking" factor.
    Ablin RJ; Bhatti RA; Bruns GR; Guinan PD
    Eur J Cancer (1965); 1977 Jul; 13(7):699-703. PubMed ID: 598395
    [No Abstract]   [Full Text] [Related]  

  • 54. [A study on cellular immunity in bladder cancer, with special reference to leukocyte adherence (author's transl)].
    Shinka T
    Nihon Hinyokika Gakkai Zasshi; 1979 May; 70(5):495-503. PubMed ID: 381740
    [No Abstract]   [Full Text] [Related]  

  • 55. Inhibition of leukocyte migration by extracts of malignant prostatic tissue and correlation of degree of in vitro sensitization to clinical responsiveness in prostatic cancer patients.
    Ablin RJ; Bush IM; Bruns GR; John T; Sadoughi N; Guinan PD
    Urology; 1978 Mar; 11(3):289-92. PubMed ID: 565097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Responsiveness of lymphocytes to soluble extracts of prostatic tumors and abrogation by serum-blocking factor(s).
    Bhatti RA; Guinan PD; McKiel CF; Bush IM; Bruns GR; Flanagan MJ; Ablin RJ
    Urology; 1977 Mar; 9(3):314-6. PubMed ID: 841812
    [TBL] [Abstract][Full Text] [Related]  

  • 57. T lymphocytes in bladder and prostatic cancer patients.
    Catalona WJ; Potvin C; Chretien PB
    J Urol; 1974 Sep; 112(3):378-82. PubMed ID: 4546938
    [No Abstract]   [Full Text] [Related]  

  • 58. Search for blocking factors in sera of patients with prostatic cancer.
    Menon M; Stefani SS
    J Urol; 1979 Oct; 122(4):503-5. PubMed ID: 90178
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hormonal epidemiology of prostatic cancer.
    Ablin RJ
    Med J Aust; 1977 Mar; 1(13):462-4. PubMed ID: 865362
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumour specificity of the SCM test for cancer diagnosis.
    Chaitchik S; Asher O; Deutsch M; Weinreb A
    Eur J Cancer Clin Oncol; 1985 Oct; 21(10):1165-70. PubMed ID: 2416568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.